Nasdaq:ASND

Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

June 13, 2026 16:00 ET  | Source: Ascendis Pharma Multi-organ system and quality-of-life benefits sustained through three and a half…

6 days ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

- Rapidly transforming into a leading global biopharma company January 09, 2026 18:01 ET  | Source: Ascendis Pharma COPENHAGEN, Denmark,…

5 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

November 25, 2025 18:15 ET  | Source: Ascendis Pharma –  Prescription Drug User Fee Act (PDUFA) goal date extended by…

7 months ago